WO1999061036A1 - Utilisation d'arabinoxylanes pour la preparation d'une composition - Google Patents
Utilisation d'arabinoxylanes pour la preparation d'une composition Download PDFInfo
- Publication number
- WO1999061036A1 WO1999061036A1 PCT/FR1999/001146 FR9901146W WO9961036A1 WO 1999061036 A1 WO1999061036 A1 WO 1999061036A1 FR 9901146 W FR9901146 W FR 9901146W WO 9961036 A1 WO9961036 A1 WO 9961036A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arabinoxylans
- fibers
- food
- soluble fibers
- substance rich
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of soluble fibers extracted from corn bran, arabinoxylans, characterized by physicochemical and metabolic properties capable of applications in the dietetic and pharmaceutical fields.
- the fibers correspond to a complex nomenclature but can be classified into two categories:
- - insoluble fibers cellulose, lignin and certain hemicelluloses
- - soluble fibers pectin, gums, some hemicelluloses.
- Insoluble fibers are mainly cereal fibers. They are characterized by their capacity of water retention, are not very fermentable and little degraded by the bacteria of the colon. They also seem to play a role in regulating transit.
- Soluble fibers are well fermentable and almost entirely degraded by colon bacteria, which promotes the growth of the bacterial population and releases volatile fatty acids, absorbed in the intestinal mucosa.
- soluble / insoluble fiber differ from one fiber and from one plant species to another (Englyst HN et al., J. Human Nutrition & Dietetics, 1988, 1, 247-286 and 2, 253-271) .
- raw plant products contain 10 to 30% dietary fiber compared to dry matter, with the exception of products rich in starch.
- Inulin is a linear polymer of fructose units linked in ⁇ l-2 and associated with an initial glucose molecule. Inulin represents the carbohydrate reserve form of plants that do not accumulate starch (Jerusalem artichoke, artichoke, onion). This oligosaccharide, due to its non-digestibility in the small intestine, has interesting nutritional effects. It is prebiotic and has effects on lowering triglyceridemia. On the other hand, its cholesterol-lowering effects are little described in the literature and the sensations of intestinal discomfort
- a dietary fiber component has not been identified which combines all the effects described above and which could be used on an industrial scale for food applications.
- such a component must also advantageously meet industrial physicochemical criteria (stability with respect to pH, viscosity), allowing the preparation of food and / or pharmaceutical products.
- the present invention specifically relates to the preparation and use of soluble fibers extracted from corn bran, rich in arabinoxylans, which have remarkable physicochemical and metabolic properties for industrial food and pharmaceutical applications.
- arabinoxylans in particular arabinoxylans of corn bran, have very advantageous properties on intestinal fermentations, the bioavailability of minerals and the metabolism of cholesterol.
- their stability, viscosity and fermentability characteristics make them particularly useful agents in the food, dietetics and pharmaceutical industry.
- the subject of the invention is therefore the use of arabinoxylans or of a substance rich in arabinoxylans for the preparation of a composition intended for preventing or treating disorders or pathologies linked to metabolic dysfunctions in humans or animal, and more particularly hypercholesterolemia.
- the invention relates very particularly to the use of soluble fibers of corn bran containing at least 60% and preferably at least 80% of arabinoxylans and having a molecular weight of between approximately 150 and 300 kD and preferably the order of 240 kD.
- Arabinoxylans and the substances containing them have remarkable physicochemical and metabolic properties, in particular a good viscosity and a resistance to acid pH and a slow fermentability with a good distribution in the colon of mammals, making it possible to confer on compositions containing them metabolic effects both on the digestion, the mineral balance and the lipid metabolism of mammals after ingestion.
- These effects relate in particular to an acidification of the medium, a production of short-chain fatty acids, an increase in solubility and the absorption of minerals, a reduction in plasma and hepatic cholesterol, correlated with increased excretion of bile acids.
- compositions useful for the preparation of food, dietetic or pharmaceutical compositions, intended for preventing or treating disorders or pathologies linked to dysfunctions metabolic in humans or animals, and more particularly hypercholesterolemia.
- compositions can contain arabinoxylans in variable amounts depending on the type of food or therapeutic product and the desired effect, for example between 2 and 20% and more, and preferably between 5% and 10%, in particular 5%.
- the invention therefore also relates to a product comprising plant fibers, such as a food or a drug, characterized in that it contains at least approximately 5% of arabinoxylans or of a substance rich in arabinoxylans, such as bran fibers of corn, defined above.
- such a product comprises a mixture of at least about 5% of arabinoxylans or of a substance rich in arabinoxylans, such as fibers of corn bran, defined above, and other rapidly fermentable and / or insoluble soluble fibers at an adequate dose and not detrimental to the qualities of said product conferred by arabinoxylans.
- the other soluble fibers are chosen from inulin and polysaccharides.
- a product of the invention combining slow soluble fibers-arabinoxylans and fast-inulin or polysaccharides for example, makes it possible to optimize the fermentation mechanisms.
- compositions of the invention are intended to prevent or treat disorders or pathologies linked to metabolic dysfunctions, of lipid, mineral or digestive type, in particular hypercholesterolemia.
- Examples of such foods include breakfast cereals, cereal bars, cookies, diet drinks, fruit juices, ready meals, confectionery and dairy products.
- FIG. 1 represents the Brookfield viscosity at 30 ° C. as a function of the concentration of arabinoxylans and of the pH.
- Figure 2 shows the evolution of the weight of the cecum and its pH during the treatment for the control regime and diet supplemented with arabinoxylan conditions.
- FIG. 3 shows the variation in the production of short chain fatty acids in the cecum during treatment for the control diet conditions and diet supplemented with arabinoxylan.
- Example 1 Extraction of arabinoxylans from corn bran.
- the plant material used consists of corn bran with the following characteristics: 90% DM (dry matter), arabinoxylans 38%, TDF (Total
- the product obtained according to this protocol has the following characteristics: 97% DM, 80% arabinoxylans, 5% cellulose, 84% TDF, ash
- Example 2 Physicochemical characteristics of the arabinoxylans of Example 1.
- the viscosity characteristics are measured with a Brookfield viscometer.
- the moderate viscosity developed by arabinoxylans allows their use in the food sector.
- the developed viscosity remains stable at acidic pH. This property of arabinoxylans allows their incorporation into certain food products of acidic nature such as milk products or fruit juices, for which inulin is unusable because of its sensitivity to acid pH.
- the arabinoxylans unlike gums which develop a very high viscosity, the arabinoxylans only introduce slight changes in texture which allows them to be used at attractive doses compared to the notion of fiber enrichment. For example, they can be introduced at a dose of 5.55 g in a 120 g yogurt so as to cover 15% of the RDI (daily intake) without modifying either the taste or the texture of the yogurt.
- arabinoxylans are variable according to the products in which they will be incorporated. However, they fall into the category of ingredients and can therefore be incorporated in a useful dose in relation to fiber enrichment.
- a bromosulfophthalein saline solution (4.7 mmol / L) is infused into one of the small veins on the surface of the cecum at a flow rate of 100 ⁇ M / min.
- This intestinal blood flow is approximately proportional to the mass of the intestinal wall (0.9-1.3 mL.min -1 .g intestinal wall -1 ).
- the blood is taken from the intestinal vein and the abdominal aorta, then placed in tubes containing heparin and centrifuged at 10,000 g for 2 minutes.
- the plasma samples are stored at 4 ° C for analysis of lipids and lipoproteins.
- a part of the livers is frozen and stored at -80 ° C for the measurement of lipids.
- the hepatic microsomes are prepared according to the method described by Younes et al. (Lipids 30, pp 847-853, 1995) and stored at -80 ° C until the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) is measured.
- HMGR 3-hydroxy-3-methylglutaryl-CoA reductase
- the protein content of the microsomes is determined using the Pierce NCA reagent kit.
- the cecum is also removed and weighed. duplicate samples are collected in 2ml microtubes immediately frozen and stored at -20 ° C. The supernatants are obtained by centrifugation at 20,000 g for 10 minutes at 4 ° C on one of the two tubes, before analysis of the short chain fatty acids (SCFA).
- SCFA short chain fatty acids
- the SCFAs are measured by gas-liquid chromatography according to Rémésy & Demigné (Biochem J. 141, pp 85-91, 1974).
- the intestinal pH becomes acidic (less than 6) after D + 3 of the arabinoxylans diet compared to the control (7,2).
- This acidification does not seem to be due to a weak lactic acid accumulation, but rather to an increase in the SCFAs produced (+280%) as shown in Figure 3.
- the presence of arabinoxylans implies a progressive increase in acetate concentrations (95 mmol / L instead of 66 mmol / L) and propionate (80 mmol / L instead of 22 mmol / L) and a decrease in the butyrate concentration (5 mmol / L instead of 12mmol / L).
- propionate is the only short-chain neoglucogenic fatty acid. and that it or its acylCoA derivatives have effects on different metabolic pathways such as neoglucogenesis, ureogenesis, ketogenesis (Rémésy and Demigné, Abbott International LTD, III, 14-21, 1989).
- the bile acids and the neutral sterols are extracted from the faeces by dispersion in 10 volumes of ethanolic KOH (0.5 M) using a Polytron homogenizer, then after a second extraction step, the samples are heated to 80 ° C. , 1 hour and centrifuged at 8000 g for 5 minutes. The concentration of bile acids is measured on this extract by the reaction catalyzed by 3-hydroxysteroid dehydrogenase (Turley and Dietschy, J.
- the cholesterol concentration is determined with a kit from the company BioMérieux (France).
- the lipids of the liver are extracted with chloroform / methanol (2: 1, vol / vol) according to the method described by Folch et al. (J. Biol. Chem. 226, 497-506, 1957).
- Plasma lipoproteins are separated by density gradient ultracentrifugation at 100,000 g for 24 h at 18 ° C on pooled samples. 24 fractions of 500 ⁇ l are stored at 4 ° C for lipid analysis.
- the activity of the liver microsomal HMGR is measured according to the method described by Wilce and Kroone (Lipoprotein analysis, Oxford University Press 1992). This is expressed in pmol of [14C] HMG-CoA transformed into [14C] mevalonactone / minute.mg of microsomal protein.
- the diet supplemented with arabinoxylans makes it possible to eliminate more cholesterol in the faeces (-26.4 ⁇ 2.7 compared to the control value - 18.8 ⁇ 1.9 ⁇ mol / D) and greater excretion of neutral steroids (cholesterol + copranostsol) 116 ⁇ mol / d for a control of 58.9 ⁇ mol / d, which corresponds to 87% of the daily consumption of cholesterol.
- HMGR microsomal activity of HMGR, practically nonexistent in the presence of cholesterol, is increased remarkably (70% increase in total steroid losses).
- the nitrogen present in the intestine and in the faeces is determined by the Kjeldahl method. According to this method, homogenized samples are treated with 36 M sulfuric acid in the presence of catalysts (K2SO4, Se). The ammonia extracted and trapped in a boric acid solution is determined by direct titration with phosphoric acid. Ca and Mg are determined on the soluble (supernatant) and total fractions of the intestine, as well as on the fecal material after treatment at 500 ° C for 10 hours. The ash obtained is taken up in a solution of lanthanum acid.
- the mineral concentration is measured by atomic absorption spectrophotometry (Perkin-Elmer 420, Norwalk, CT) at the following wavelengths: 422 for Ca and 285 for Mg.
- No modification in the Ca caecal pool was observed during the first phase of adaptation to the arabinoxylan diet.
- an increase (17 times) in the pool of caecal soluble Ca is noted on D + 3.
- the increase in the caecal volume and the pool of soluble Ca results in the net increase in the caecal absorption (3 times) of this cation.
- the SCFAs could also have a direct influence on the absorption of Ca by modifying the exchanges of electrolytes. This Ca effect can result in a decrease in the solubility of bile acids, which promotes their faecal elimination. Other benefits of Ca have been reported:
- the intestinal Mg does not follow the same evolution. Indeed, its total concentration is not modified, however the soluble concentration reaches at d + 3 a value fivefold (70 ⁇ mol) of the control value.
- the intestinal absorption of Mg is increased in the presence of arabinoxylans 0.23 ⁇ 0.02 ⁇ mol / min for 0.05 ⁇ 0.01 ⁇ mol / min (control).
- fermentable carbohydrates play an important role in increasing mineral absorption in the large intestine and this effect is of great interest when the digestive absorption mechanisms are inoperative, as for example in the elderly.
- Arabinoxylans with a molecular weight of approximately 240 kD are well fermentable with a good distribution of fermentations (moderately acidic pH) throughout the colon, unlike inulin which is almost entirely fermented in the proximal part of the colon.
- Arabinoxylans ferment more slowly by colon bacteria, then designated slow soluble fibers, are therefore likely to cause less discomfort than inulin after ingestion of products containing them.
- Example 4 Measurement of the bifidoqene effects of arabinoxylans.
- arabinoxylans are fermented by the colonic flora, which is a complex mixture of different bacteria whose activity plays an important role in health. In vitro tests were conducted according to the protocol described below to show the stimulating effect of arabinoxylans on the colonic flora and in particular on bifidobacterium spp. .
- Arabinoxylans a source of carbon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000550496A JP2002516286A (ja) | 1998-05-22 | 1999-05-12 | 組成物調製のためのアラビノキシランの使用 |
AU36119/99A AU3611999A (en) | 1998-05-22 | 1999-05-12 | Use of arabinoxylans for preparing a composition |
EP99918064A EP1077714A1 (fr) | 1998-05-22 | 1999-05-12 | Utilisation d'arabinoxylanes pour la preparation d'une composition |
CA002332617A CA2332617A1 (fr) | 1998-05-22 | 1999-05-12 | Utilisation d'arabinoxylanes pour la preparation d'une composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/06469 | 1998-05-22 | ||
FR9806469A FR2778849B1 (fr) | 1998-05-22 | 1998-05-22 | Utilisation d'arabinoxylanes pour la preparation d'une composition destinee a prevenir ou traiter des desordres ou des pathologies lies a des dysfonctionnements metaboliques |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999061036A1 true WO1999061036A1 (fr) | 1999-12-02 |
Family
ID=9526610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001146 WO1999061036A1 (fr) | 1998-05-22 | 1999-05-12 | Utilisation d'arabinoxylanes pour la preparation d'une composition |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1077714A1 (fr) |
JP (1) | JP2002516286A (fr) |
AU (1) | AU3611999A (fr) |
CA (1) | CA2332617A1 (fr) |
FR (1) | FR2778849B1 (fr) |
WO (1) | WO1999061036A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2811911A1 (fr) * | 2000-07-24 | 2002-01-25 | Rhodia Food S A S | Dispersions comprenant au moins un agent emulsifiant choisi parmi les polysaccharides, le polysaccharide etant un heteroxylane |
WO2002035945A2 (fr) * | 2000-11-02 | 2002-05-10 | K.U.Leuven Research And Development | Procede pour preparer des pates presentant un taux plus eleve de fibres solubles |
JP2004504824A (ja) * | 2000-07-28 | 2004-02-19 | ファーマバイト エルエルシー | 繊維処方 |
JP2004520318A (ja) * | 2000-12-27 | 2004-07-08 | エヌ・ヴイ・ヌートリシア | オリゴ糖を含有する健康増進作用を有する栄養組成物 |
WO2010020639A1 (fr) * | 2008-08-18 | 2010-02-25 | Bioactor Bvba | Arabinoxylanes pour moduler la fonction barrière de la surface intestinale |
WO2011020853A1 (fr) * | 2009-08-18 | 2011-02-24 | Cosucra-Groupe Warcoing Sa | Compositions contenant des mélanges de fibres fermentescibles |
CN108902970A (zh) * | 2018-06-27 | 2018-11-30 | 安徽瑞康食品生物科技有限公司 | 含有戊聚糖的食用组合物,功能食品及其制备方法、用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150010672A1 (en) * | 2009-05-29 | 2015-01-08 | Purdue Research Foundation | Slowly Fermentable Soluble Dietary Fiber |
US20100303953A1 (en) * | 2009-05-29 | 2010-12-02 | Purdue Research Foundation | Slowly fermentable soluble dietary fiber |
CN113287713A (zh) * | 2021-05-27 | 2021-08-24 | 唐传生物科技(厦门)有限公司 | 一种仿生高纤复合面粉原料及用途 |
-
1998
- 1998-05-22 FR FR9806469A patent/FR2778849B1/fr not_active Expired - Fee Related
-
1999
- 1999-05-12 EP EP99918064A patent/EP1077714A1/fr not_active Withdrawn
- 1999-05-12 CA CA002332617A patent/CA2332617A1/fr not_active Abandoned
- 1999-05-12 JP JP2000550496A patent/JP2002516286A/ja not_active Withdrawn
- 1999-05-12 AU AU36119/99A patent/AU3611999A/en not_active Abandoned
- 1999-05-12 WO PCT/FR1999/001146 patent/WO1999061036A1/fr not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
KAZUHIKO NISHITANI ET AL.: "ENZYMIC ANALYSIS OF FERULOYLATED ARABINOXYLANS (FERAXAN) DERIVED FROM ZEA MAYS CELL WALLS.", PLANT PHYSIOL., vol. 91, 1989, pages 242 - 248, XP002092235 * |
P. MARTEAU ET AL.: "DIGESTIBILITY AND BULKING EFFECT OF ISPAGHULA HUSKS IN HEALTHY HUMANS.", GUT, vol. 35, 1994, pages 1747 - 1752, XP002092236 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002007869A1 (fr) * | 2000-07-24 | 2002-01-31 | Rhodia Chimie | Dispersion comprenant un heteroxylane comme agent emulsifiant |
FR2811911A1 (fr) * | 2000-07-24 | 2002-01-25 | Rhodia Food S A S | Dispersions comprenant au moins un agent emulsifiant choisi parmi les polysaccharides, le polysaccharide etant un heteroxylane |
JP2004504824A (ja) * | 2000-07-28 | 2004-02-19 | ファーマバイト エルエルシー | 繊維処方 |
WO2002035945A2 (fr) * | 2000-11-02 | 2002-05-10 | K.U.Leuven Research And Development | Procede pour preparer des pates presentant un taux plus eleve de fibres solubles |
WO2002035945A3 (fr) * | 2000-11-02 | 2002-08-01 | Leuven K U Res & Dev | Procede pour preparer des pates presentant un taux plus eleve de fibres solubles |
US8227448B2 (en) | 2000-12-27 | 2012-07-24 | N.V. Nutricia | Nutritional composition with health promoting action containing oligosaccharides |
JP2004520318A (ja) * | 2000-12-27 | 2004-07-08 | エヌ・ヴイ・ヌートリシア | オリゴ糖を含有する健康増進作用を有する栄養組成物 |
WO2010020639A1 (fr) * | 2008-08-18 | 2010-02-25 | Bioactor Bvba | Arabinoxylanes pour moduler la fonction barrière de la surface intestinale |
US8465788B2 (en) | 2008-08-18 | 2013-06-18 | Bioactor B.V. | Arabinoxylans for modulating the barrier function of the intestinal surface |
US20120135957A1 (en) * | 2009-08-18 | 2012-05-31 | Df3 Sas | Compositions containing mixtures of fermentable fibers |
BE1019755A3 (fr) * | 2009-08-18 | 2012-12-04 | Cosucra Groupe Warcoing S A | Compositions contenant des melanges de fibres fermentescibles. |
WO2011020853A1 (fr) * | 2009-08-18 | 2011-02-24 | Cosucra-Groupe Warcoing Sa | Compositions contenant des mélanges de fibres fermentescibles |
US9364538B2 (en) | 2009-08-18 | 2016-06-14 | Cosucra-Groupe Warcoing Sa | Compositions containing mixtures of fermentable fibers |
EP2467145B1 (fr) | 2009-08-18 | 2017-01-25 | Cosucra-groupe Warcoing Sa | Compositions contenant des mélanges de fibres fermentables |
EP2467145B2 (fr) † | 2009-08-18 | 2020-02-05 | Cosucra-groupe Warcoing Sa | Compositions contenant des mélanges de fibres fermentables |
US10660913B2 (en) * | 2009-08-18 | 2020-05-26 | Cosucra-Groupe Warcoing Sa | Compositions containing mixtures of fermentable fibers |
CN108902970A (zh) * | 2018-06-27 | 2018-11-30 | 安徽瑞康食品生物科技有限公司 | 含有戊聚糖的食用组合物,功能食品及其制备方法、用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2002516286A (ja) | 2002-06-04 |
FR2778849B1 (fr) | 2001-05-11 |
CA2332617A1 (fr) | 1999-12-02 |
EP1077714A1 (fr) | 2001-02-28 |
FR2778849A1 (fr) | 1999-11-26 |
AU3611999A (en) | 1999-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006231557B2 (en) | A method and composition for nutritionally improving glucose control and insulin action | |
US8465788B2 (en) | Arabinoxylans for modulating the barrier function of the intestinal surface | |
EP1161157A1 (fr) | Complement alimentaire et procede de traitement cosmetique a base d'un extrait de raisin riche en polyphenols | |
WO1999061036A1 (fr) | Utilisation d'arabinoxylanes pour la preparation d'une composition | |
CA2515290A1 (fr) | Huiles enrichies avec des diacylglyceroles et des esters de phytosterol utilisees dans la diminution du cholesterol et des triglycerides | |
EP2217255B1 (fr) | Utilisation de phytoecdysones dans la preparation d'une composition pour agir sur le syndrome metabolique | |
US20080176819A1 (en) | Method of preventing or treating metabolic syndrome | |
AU2012261503B2 (en) | A method and composition for nutritionally improving glucose control and insulin action | |
JP3393693B2 (ja) | 脂質増加抑制剤 | |
WO2001074371A1 (fr) | Mucilages et galactomannanes de fenugrec et leurs applications | |
US20090010892A1 (en) | Hyperlipidemia Treatment Agent | |
US20060127449A1 (en) | Method and composition for lowering cholesterol | |
US20080280854A1 (en) | Preventing or reducing oxidative stress or oxidative cell injury | |
Bahnasy et al. | Effect of quinoa (Chenopodium quinoa) on Lipid Profile in Rats Exposed to twoSynthetic Food colors | |
WO1981001355A1 (fr) | Medicament a base de fibres vegetales | |
WO2004056210A1 (fr) | Utilisation de prebiotiques pour prevenir ou traiter le stress oxydant | |
Fremont | Acacia gum, the natural multifunctional fibre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2332617 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999918064 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09717471 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 36119/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999918064 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999918064 Country of ref document: EP |